Determining feasibility of randomisation to high vs. ad libitum water intake in Polycystic Kidney Disease: the DRINK Randomised Feasibility Trial
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a common inherited condition where unrelenting cyst growth can cause kidney failure. Some research suggests that drinking water beyond the point of thirst can slow cyst growth by suppressing the hormone vasopressin.
Proposed by the UK PKD Charity, DRINK assessed if ADPKD patients could reliably drink enough water to warrant a large-scale trial. 42 participants were divided into ‘high’ and ‘ad libitum’ water intake groups. Participants recorded their own data through a smartphone app for 8 weeks and attended 3 clinical assessments. Our trial team found that the ‘high water’ group was able to maintain dilute urine at a level signifying reduced vasopressin production. Recruitment was successful and trial arms clearly separated, indicating a large-scale water intake trial is feasible.
Funding was provided by the British Renal Society and Kidney Care UK (formerly British Kidney Patient Association) grant programme, PKD Charity, Addenbrooke’s Charitable Trust, and Kidney Research UK. Trial registration NCT02933268 and ISCRTN16794957. Contact PKD Charity if you’d like to be involved in upcoming research.